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ABSTRACT
Background. CheckMate 040 assessed the efficacy and safety
of nivolumab in patients with advanced hepatocellular carci-
noma (HCC). Understanding the safety profile of nivolumab is
needed to support the management of treatment-related
adverse events (TRAEs). This analysis assessed the safety
of nivolumab monotherapy in the phase I/II, open-label
CheckMate 040 study.
Materials and Methods. Select TRAEs (sTRAEs; TRAEs with
potential immunologic etiology requiring more frequent
monitoring) occurring between first dose and 30 days after
last dose were analyzed in patients in the dose-escalation
and -expansion phases. Time to onset (TTO), time to resolu-
tion (TTR), and recurrence of sTRAEs were assessed, and
the outcome of treatment with immune-modulating medi-
cation (IMM) was evaluated.
Results. The analysis included 262 patients. The most com-
mon sTRAE was skin (35.5%), followed by gastrointestinal
(14.5%) and hepatic (14.1%) events; the majority were grade
1/2, with 10.7% of patients experiencing grade 3/4 events.
One patient had grade 5 pneumonitis. Median (range) TTO
ranged from 3.6 (0.1–59.9) weeks for skin sTRAEs to 47.6
(47.1–48.0) weeks for renal sTRAEs. Overall, 68% of sTRAEs
resolved, with median (range) TTR ranging from 3.7
(0.1–123.3+) weeks for gastrointestinal sTRAEs to 28.4
(0.1–79.1) weeks for endocrine sTRAEs. Most gastrointestinal
and all hepatic events resolved with treatment in accordance
with established toxicity management algorithms. In
57 patients (40%), sTRAEs were managed with IMM.
Reoccurrence of sTRAEs was uncommon following rechallenge
with nivolumab.
Conclusion. Nivolumab demonstrated a manageable safety
profile in this analysis of patients with advanced HCC. A
majority of sTRAEs resolved with treatment. The Oncologist
2020;25:e1532–e1540
Implications for Practice: Nivolumab is a viable treatment option for patients with previously treated advanced hepatocel-
lular carcinoma as it has demonstrated durable tumor responses and promising survival. Nivolumab has a manageable
safety profile. The most common select treatment-related adverse events (sTRAEs) in this analysis were skin related (35%).
Gastrointestinal and hepatic sTRAEs were observed in approximately 14% of patients. The majority of sTRAEs resolved
(68%). Safety events are easier to manage if addressed early. Patient education on signs and symptoms to watch out for
and the importance of early reporting and consultation should be emphasized.
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Hepatobiliary
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common cause
of primary liver cancer and the second most common cause
of cancer-related mortality worldwide [1, 2]. HCC is often
diagnosed at an advanced stage, for which effective treat-
ment options are limited [1, 3]. However, even with limited
treatment options, the risks and benefits must be carefully
considered, as most patients with HCC suffer from concomi-
tant cirrhosis and its attendant liver dysfunction.
Immune checkpoint inhibitors, such as programmed cell
death 1 (PD-1) inhibitors, have dramatically improved outcomes
in a variety of cancer types [4]. In patients with advanced HCC
who were previously treated with sorafenib, the international
phase I/II CheckMate 040 study demonstrated that treatment
with the PD-1 inhibitor nivolumab was associated with durable
objective responses (which could have positively impacted sur-
vival) and a manageable safety profile [3]. The objective
response rate (ORR) was 15% in the dose-escalation phase and
20% in the dose-expansion phase in patients treated with
nivolumab 3 mg/kg. The 9-month overall survival rates were
66% and 74%, respectively. On the basis of these results,
nivolumab received accelerated approval from the U.S. Food
and Drug Administration for use in patients with HCC who have
been previously treated with sorafenib [5]. Nivolumab was sub-
sequently approved for the same indication in other countries,
including Canada,Taiwan, and Australia [6,7].
Because of their mechanism of action, immune checkpoint
inhibitors are associated with adverse events (AEs) that differ
from those associated with cytotoxic chemotherapy or tyro-
sine kinase inhibitors. These AEs can affect multiple organ sys-
tems and, if moderate or severe, can result in substantial
morbidity and potential mortality [8]. Consequently, early
identification and management of treatment-related AEs
(TRAEs) in patients receiving immune checkpoint inhibitors are
essential to prevent treatment delays and improve outcomes.
The purpose of the current analysis was to assess the safety
profile of nivolumab in the CheckMate 040 study after a
median follow-up of 19.4 months (March 2017 database lock).
Particular attention was paid to select TRAEs (sTRAEs) with an
immunologic etiology, specifically endocrine, gastrointestinal,
hepatic, pulmonary, renal, and skin sTRAEs. These sTRAEs
require greater awareness from patients and caregivers to
optimize detection and early management.
MATERIALS AND METHODS
Study Design
CheckMate 040 (NCT01658878) was a phase I/II, open-label
study of nivolumab in patients with advanced HCC. The study
consisted of a dose-escalation phase conducted in four coun-
tries (U.S., Spain, Hong Kong, and Singapore) and a dose-
expansion phase conducted in 11 countries (the four men-
tioned above plus Canada, U.K., Germany, Italy, Japan, South
Korea, and Taiwan; 39 sites in total). During the dose-
escalation phase, sequential groups of patients received intra-
venous (IV) nivolumab 0.1 mg/kg, 0.3 mg/kg, 1.0 mg/kg, 3.0
mg/kg, or 10.0 mg/kg every 2 weeks in a 3 + 3 design. During
the dose-expansion phase, all patients received nivolumab 3.0
mg/kg IV every 2 weeks. Ongoing randomized phases of
CheckMate 040 include additional treatment arms (including
nivolumab in combination with ipilimumab and/or cabozantinib);
however, because these fall outside the remit of this safety
analysis, they will be discussed in a future study. The primary
study objectives were to assess safety and tolerability in the
dose-escalation phase and ORR in the dose-expansion phase.
Figure 1. Hepatic adverse event management algorithm.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; CTCAE, Common Terminology
Criteria for Adverse Events; NCI, National Cancer Institute; ULN, upper limit of normal.
© 2020 The Authors.
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Table 1. Summary of sTRAEs by CTCAE grade
On treatmenta (N = 262) Treatment discontinuedb (N = 226)
sTRAEs Any grade, n (%) Grade 3/4, n (%) Any grade, n (%) Grade 3/4, n (%)
Total patients with ≥1 sTRAEc 143 (54.6) 28 (10.7) 35 (15.5) 13 (5.8)
Skin 93 (35.5) 5 (1.9) 12 (5.3) 2 (0.9)
Pruritus 56 (21.4) 1 (0.4) 7 (3.1) 1 (0.4)
Rash 46 (17.6) 2 (0.8) 2 (0.9) 0
Rash maculopapular 9 (3.4) 0 1 (0.4) 0
Erythema 3 (1.1) 1 (0.4) 1 (0.4) 0
Rash pruritic 3 (1.1) 0 1 (0.4) 0
Psoriasis 3 (1.1) 1 (0.4) 2 (0.9) 1 (0.4)
Skin exfoliation 2 (0.8) 0 0 0
Rash papular 2 (0.8) 0 0 0
Eczema 1 (0.4) 0 0 0
Dermatitis 1 (0.4) 0 0 0
Palmar-plantar erythrodysesthesia syndrome 1 (0.4) 0 0 0
Rash erythematosus 1 (0.4) 0 0 0
Skin hypopigmentation 1 (0.4) 0 0 0
Gastrointestinal 38 (14.5) 3 (1.1) 3 (1.3) 1 (0.4)
Diarrhea 36 (13.7) 3 (1.1) 3 (1.3) 1 (0.4)
Colitis 2 (0.8) 1 (0.4) 0 0
Enteritis 1 (0.4) 0 0 0
Frequent bowel movements 1 (0.4) 0 0 0
Hepatic 37 (14.1) 17 (6.5) 13 (5.8) 7 (3.1)
AST increased 26 (9.9) 14 (5.3) 7 (3.1) 4 (1.8)
ALT increased 25 (9.5) 9 (3.4) 6 (2.7) 4 (1.8)
Blood bilirubin increased 7 (2.7) 1 (0.4) 4 (1.8) 0
Blood alkaline phosphatase increased 6 (2.3) 0 1 (0.4) 0
Hyperbilirubinemia 3 (1.1) 0 2 (0.9) 0
Hepatitis 1 (0.4) 1 (0.4) 2 (0.9) 2 (0.9)
Liver disorder 1 (0.4) 0 1 (0.4) 0
Gamma-glutamyltransferase increased 1 (0.4) 1 (0.4) 0 0
Liver function test increased 1 (0.4) 1 (0.4) 1 (0.4) 1 (0.4)
Endocrine 25 (9.5) 2 (0.8) 3 (1.3) 2 (0.9)
Endocrine disorders 16 (6.1) 1 (0.4) 0 0
Hypothyroidism 10 (3.8) 0 1 (0.4) 0
Hyperthyroidism 2 (0.8) 0 0 0
Adrenal insufficiency 2 (0.8) 1 (0.4) 1 (0.4) 1 (0.4)
Secondary adrenocortical insufficiency 1 (0.4) 0 0 0
Autoimmune hypothyroidism 1 (0.4) 0 0 0
Autoimmune thyroiditis 1 (0.4) 0 0 0
Investigations 7 (2.7) 0 0 0
Blood TSH increased 5 (1.9) 0 0 0
Blood TSH decreased 2 (0.8) 0 0 0
Metabolism and nutrition disorders 2 (0.8) 1 (0.4) 0 0
Diabetes mellitus 2 (0.8) 1 (0.4) 1 (0.4) 1 (0.4)
Pulmonary 3 (1.1) 1 (0.4) 4 (1.8) 2 (0.9)
Pneumonitisd 3 (1.1) 1 (0.4) 4 (1.8) 2 (0.9)
Renal 2 (0.8) 0 1 (0.4) 0
Blood creatinine increased 2 (0.8) 0 0 0
Autoimmune nephritis 0 0 1 (0.4) 0
aEvents reported between first dose and 30 days after last dose of nivolumab.
bEvents reported between last dose of nivolumab and 100 days after last dose.
cPatients may have experienced sTRAEs in multiple categories.
dOne case of grade 5 pneumonitis occurred more than 30 days after last day of treatment.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events;
sTRAE, select treatment-related adverse event; TSH, thyroid-stimulating hormone.
© 2020 The Authors.
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Full details of the study design and results have been
reported previously [3].
Patients
Adults with histologically confirmed, advanced HCC not
amenable to curative resection were eligible for the study.
Patients could be either sorafenib naive or experienced
(progressed on or intolerant of sorafenib) and were eligible
irrespective of hepatitis C virus or hepatitis B virus (HBV)
status; patients with HBV were required to have an HBV
DNA level less than 100 IU/mL. Patients were required to
have Child-Pugh scores of 7 or less for the dose-escalation
phase and scores of 6 or less for the dose-expansion phase.
Full eligibility criteria have been reported previously [3].
Safety Assessments
Safety was assessed between the first dose and up to 100 days
after the last dose of nivolumab. The analysis of TRAEs included
events occurring between the first dose and 30 days after the
last dose of study therapy, or until all TRAEs were resolved
(complete resolution or improvement to baseline grade) or
deemed irreversible by the investigator. For sTRAEs (AEs with a
Figure 2. Time to onset (TTO) of any-grade sTRAEs. TTO was defined as the time between the first dose of study treatment and
onset of earliest sTRAE in the category. Data are presented as medians with interquartile range (boxes) and range (bars).
Abbreviations: IQR, interquartile range; sTRAE, select treatment-related adverse event.





of sTRAEs after IMM, n/n (%)
Median TTR after
IMM (range), wk
Total patients with ≥1 sTRAEb (n = 143) 57/143 (39.9) 41/57 (71.9) 18.1 (0.1–88.3+)
Skin (n = 93) 41/93 (44.1) 27/41 (65.9) 20.7 (0.1–88.3+)
Topical corticosteroidsc 38/93 (40.9)
Systemic corticosteroidsd 4/93 (4.3)
Cyclosporine 1/93 (1.1)
Ophthalmologic medication 2/93 (2.2)
Gastrointestinal (n = 38) 6/38 (15.8) 5/6 (83.3) 5.1 (1.6–31.6+)
Systemic corticosteroidsd 6/38 (15.8)
Hepatic (n = 37) 7/37 (18.9) 7/7 (100.0) 19.4 (2.4–35.9)
Systemic corticosteroidsd 7/37 (18.9)
Mycophenolic acid 1/37 (2.7)
Endocrine (n = 25) 3/25 (12.0) 2/3 (66.7) 30.1 (0.4–38.3+)
Systemic corticosteroidsd 3/25 (12.0)
Pulmonary (n = 3) 2/3 (66.7) 1/2 (50.0) NA (0.6–70.9+)
Systemic corticosteroidsd 2/3 (66.7)
Renal (n = 2) 0/2 (0.0)
aResolution was defined as complete resolution or improvement to baseline grade.
bPatients may have experienced sTRAEs in multiple categories.
cIncludes topical betamethasone, clobetasol, dexamethasone, fluocinolone, fluocinonide, hydrocortisone, methylprednisolone, mometasone,
prednicarbate, and triamcinolone.
dIncludes systemic budesonide, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and prednisone.
Abbreviations: IMM, immune-modulating medications; NA, not achieved; sTRAE, select treatment-related adverse event; TTR, time to
resolution.
© 2020 The Authors.
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potential inflammatory mechanism requiring more frequent
monitoring and/or unique intervention such as immunosup-
pressants and/or endocrine replacement therapy), the time to
onset (TTO; defined as the time between the first dose of study
treatment and the earliest onset of sTRAE in the category) and
time to resolution (TTR; defined as the longest time from sTRAE
onset to complete resolution or improvement to baseline
grade) were recorded. For patients with dose delays due to
sTRAEs, all sTRAEs occurring after resumption of nivolumab
were documented. The reoccurrence of sTRAEs in patients who
received nivolumab following the onset and resolution of an ini-
tial sTRAE (rechallenge) was also recorded. Medications used to
manage the sTRAEs and whether the medications led to resolu-
tion of the sTRAEs were also evaluated. All sTRAEs were graded
using National Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0.
Management of Select Treatment-Related Adverse
Events
Select TRAEs were managed using protocol-specified algo-
rithms, which included the use of immune-modulating medi-
cation (IMM) [9]. The algorithm for management of hepatic
sTRAEs was modified from the nivolumab development pro-
gram algorithm to account for potential baseline abnormali-
ties in liver function, which are common in patients with
HCC. In this modified algorithm (Fig. 1), aspartate amino-
transferase (AST)/alanine aminotransferase (ALT) monitoring
was recommended to be performed every 3 days for
patients with hepatic AEs. Nivolumab doses were
recommended to be delayed when a two-grade shift of
AST/ALT levels from a baseline event of grade 0 or 1 was
observed (based on NCI CTCAE criteria). For patients with
baseline AST or ALT within the grade 2 toxicity range, doses
had to be delayed for increases in AST or ALT at 2 × baseline
value or when AST or ALT was 8 × upper limit of normal
(ULN; whichever was lower). Corticosteroid treatment had to
be initiated when a dose delay of 3–5 days did not improve
AST/ALT levels or when AST/ALT levels exceeded 8 × ULN.
Nivolumab treatment could be resumed when AST/ALT
returned to near baseline levels, provided the criteria for dis-
continuation had not been met.
Statistical Analyses
Statistical analyses of safety data were purely descriptive;
sTRAEs were tabulated by frequency and severity and by system
organ class and preferred term. The current analysis includes
data from all patients in the intent-to-treat population.
Study Oversight
This study was approved by the institutional review board
or independent ethics committee at each participating cen-
ter and was conducted in accordance with Good Clinical
Practice guidelines, as defined by the International Council
on Harmonisation, and with the principles of the Declara-
tion of Helsinki. All patients provided written informed con-
sent prior to enrollment.
RESULTS
Patients
A total of 262 sorafenib-naive or -experienced (progressed on
or intolerant of sorafenib) patients were included in the
intent-to-treat population, with 48 treated in the dose-
escalation phase and 214 in the dose-expansion phase.
Median age was 63 years, and 98.5% of patients had a Child-
Pugh score of 5–6 (class A). Eastern Cooperative Oncology
Group performance status was 0 or 1 for all patients. Patients
received nivolumab treatment for a median of 4.9 months
(range, 0–37.4+): 162 patients (61.8%) were treated for more
than 3 months, and 27 patients (10.3%) were treated for lon-
ger than 18 months. At database lock in March 2017, the
median duration of follow-up for the overall population was
19.4 months (range, 16.2–51.7).
Safety
Select TRAEs occurred in 143 patients (54.6%), and grade
3/4 sTRAEs occurred in 28 patients (10.7%). Ten patients
(6.8%) were hospitalized (or had hospitalization prolonged)
Figure 3. Time to resolution (TTR) of any-grade sTRAEs. TTR was defined as the longest time from onset to complete resolution or
improvement to baseline grade. Data are presented as medians with interquartile range (boxes) and range (bars).
Abbreviations: IQR, interquartile range; NA, not achieved; sTRAE, select treatment-related adverse event.
© 2020 The Authors.
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because of sTRAEs. The most frequently reported sTRAEs
were skin (35.5% of patients), gastrointestinal (14.5%), and
hepatic (14.1%; Table 1). The most common skin sTRAEs
were pruritus (21.4%) and rash (17.6%), whereas diarrhea
(13.7%) was the most common gastrointestinal sTRAE. Ele-
vations of ALT and AST were the most common hepatic
sTRAEs, occurring in 25 (9.5%) and 26 patients (9.9%),
respectively. The most frequent grade 3/4 sTRAEs were
hepatic AEs (6.5%). Grade 3/4 elevations of ALT and AST
occurred in 3.4% and 5.3% of patients, respectively. Gener-
ally, safety profiles were similar across the different etiolo-
gies of HCC (data not shown).
Over 100 days of follow-up after the last dose of
nivolumab, 35 of 226 (15.5%) patients had an sTRAE, of
which 13 patients (5.8%) had a grade 3/4 event. The most
common any-grade sTRAEs reported after treatment discon-
tinuation were AST increased (3.1% of patients), pruritus
(3.1%), ALT increased (2.7%), pneumonitis (1.8%), blood bili-
rubin increased (1.8%), and diarrhea (1.3%; Table 1). One
patient died of an sTRAE (grade 5 pneumonitis) that occurred
more than 100 days after discontinuation of nivolumab
because of disease progression and after subsequent treat-
ment with sorafenib. This event was considered by investi-
gators to be related to both nivolumab and sorafenib
treatment.
The TTOs of sTRAEs (any grade) are shown in Figure 2.
With the exception of endocrine AEs, sTRAEs generally
occurred within the first 4–12 weeks of nivolumab treat-
ment. The median (range) TTO ranged from 3.6 (0.1–59.9)
weeks for skin sTRAEs to 47.6 (47.1–48.0) weeks for renal
sTRAEs. The median (range) TTO of endocrine and hepatic
sTRAEs was 18.3 (2.0–71.0) weeks and 6.0 (0.1–57.1) weeks,
respectively.
A summary of IMM used to treat any-grade sTRAEs is
shown in Table 2. Overall, 57 patients (39.9%) with sTRAEs
received IMM; sTRAEs resolved after IMM treatment in
41 patients (71.9%). Of the 57 patients who received IMM
for an sTRAE, 11 progressed; the median (range) time to
progression after IMM use was 10.4 (1–88) weeks.
The most common sTRAE category for which patients
received IMM treatment was skin, with 41 of 93 patients
(44.1%) receiving IMM. However, proportionally, the highest
rate of IMM use was for pulmonary AEs, with two-thirds of
patients (66.7%) receiving IMM. Across all sTRAE categories,
the majority of patients requiring IMM therapy received
corticosteroids. For skin sTRAEs, 38 of 93 patients (40.9%)
received topical corticosteroids, and 4 of 93 (4.3%) received
systemic corticosteroids; cyclosporine (1/93; 1.1%) was also
used for the treatment of skin sTRAEs. Systemic corticoste-
roids were the only treatment used for gastrointestinal
(6/38 patients; 5 resolved), endocrine (3/25; 2 resolved),
and pulmonary (2/3; 1 resolved) sTRAEs. Seven of 37 patients
who experienced a hepatic sTRAE received systemic cortico-
steroids (all resolved), of which 1 patient also received
mycophenolic acid for a grade 4 ALT elevation (the event
resolved 3 days after treatment).
Gastrointestinal sTRAEs resolved the fastest, whereas
endocrine sTRAEs resolved the slowest. The median (range)
time to resolution of any-grade sTRAEs ranged from 3.7
(0.1–123.3+) weeks for gastrointestinal events to 28.4 (0.1–
79.1) weeks for endocrine events (Figure 3). Resolution
times (range) for any-grade sTRAEs that occurred most fre-
quently in skin, gastrointestinal, and hepatic categories
were 23.1 (0.1–143.9+) weeks for pruritus, 7.0 (0.1–64.3+)
for rash, 3.6 (0.1–123.3+) for diarrhea, 4.2 (0.7–71.1+) for
AST increased, and 8.1 (2.0–69.9+) for ALT increased. The
time to resolution for hypothyroidism (the most common
endocrine sTRAE) ranged from 3.0+ to 79.1+ weeks (the
median could not be estimated). The percentage of sTRAEs
(any grade) that resolved after a median follow-up of
19.4 months ranged from 50.0% (1/2 AEs) for renal sTRAEs
to 78.4% (29/37 AEs) for gastrointestinal sTRAEs. For grade
3/4 sTRAEs, the corresponding resolution rates ranged from
50% (1/2 AEs) for endocrine sTRAEs to 100% (1/1 AE) for
pulmonary sTRAEs. For hepatic sTRAEs, the resolution rates
Table 3. Summary of sTRAEs leading to dose delay,







Total patients with ≥1 sTRAE
leading to dose delaya
30 (11.5) 16 (6.1)
Skin (n = 93) 6 (6.5) 4 (4.3)
Pruritus 2 (2.2) 1 (1.1)
Rash 2 (2.2) 1 (1.1)
Erythema 1 (1.1) 1 (1.1)
Psoriasis 1 (1.1) 1 (1.1)
Gastrointestinal (n = 38) 6 (15.8) 1 (2.6)
Diarrhea 5 (13.2) 0
Colitis 1 (2.6) 1 (2.6)
Hepatic (n = 37) 14 (37.8) 9 (24.3)
AST increased 10 (27.0) 8 (21.6)
ALT increased 7 (18.9) 4 (10.8)




Hepatitis 1 (2.7) 1 (2.7)
Liver disorder 1 (2.7) 0
Endocrine (n = 25) 3 (12.0) 2 (8.0)
Hypothyroidism 1 (4.0) 0
Adrenal insufficiency 1 (4.0) 1 (4.0)
Diabetes mellitus 1 (4.0) 1 (4.0)
Pulmonary (n = 3) 1 (33.3) 0
Pneumonitis 1 (33.3) 0
Renal (n = 2) 1 (50.0) 0
Blood creatinine increased 1 (50.0) 0
aPatients may have experienced sTRAEs in multiple categories.
Includes events reported between first dose and 30 days after last
dose of study therapy.
Dose delay was defined as a delay exceeding 3 days and determina-
tion of dose delay was based on investigator assessment. Percent-
ages are calculated based on total numbers of patients having a
sTRAE in the category.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate ami-
notransferase; sTRAE, select treatment-related adverse event.
© 2020 The Authors.
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were 70.3% (26/37 AEs) for any-grade sTRAEs and 88.2%
(15/17 AEs) for grade 3/4 sTRAEs.
The median (range) TTR for sTRAEs treated with IMM
ranged from 5.1 (1.6–31.6+) weeks for gastrointestinal events to
30.1 (range 0.4–38.3+) weeks for endocrine events (Table 2).
Table 3 shows sTRAEs leading to dose delay. Overall,
30 (11.5%) patients had sTRAEs that led to a delay in treat-
ment; 16 (6.1%) of these patients had grade 3/4 sTRAEs.
Hepatic sTRAEs were the most common cause of dose delays,
occurring in 14 of 37 (37.8%) patients with any-grade hepatic
sTRAEs. The most frequent grade 3/4 sTRAEs leading to dose
delay were elevations in AST (21.6%) and ALT (10.8%).
Reoccurrence of sTRAEs in patients who received
nivolumab following resolution of the initial event (rechallenge)
was low (Table 4). Of the 18 patients who were rechallenged
with nivolumab following a hepatic sTRAE, 2 (11.1%) had a
reoccurring event (Table 4). No other sTRAEs reoccurred fol-
lowing rechallenge.
DISCUSSION
Data from the dose-escalation and -expansion cohorts of
CheckMate 040 indicate that the safety profile of nivolumab,
based on sTRAEs, in sorafenib-naive or -experienced patients
with advanced HCC is generally consistent with the safety pro-
files of nivolumab in other tumor types, including unresectable
or metastatic melanoma, metastatic non-small cell lung cancer,
advanced renal cell carcinoma, Hodgkin lymphoma, squamous
cell carcinoma of the head and neck, advanced or metastatic
urothelial carcinoma, and colorectal cancer [5]. Hepatic sTRAEs
occurred at a higher frequency in the current patient popula-
tion; however, these events were reversible and manageable
and rarely led to treatment discontinuation. No new safety sig-
nals emerged during a median follow-up of 19.4 months.
Around half of all patients experienced an sTRAE
(~55%). This highlights the importance of educating patients
on potential AEs to encourage earlier reporting that could
facilitate better management. It is encouraging that most
sTRAEs were mild (i.e., grade 1/2).
In general, sTRAEs occurred within the first 4–12 weeks of
treatment; it is particularly important for the patient and
caregivers to pay attention to signs and symptoms of potential
AEs during this period. Time to onset varied by category. Skin
sTRAEs occurred earliest (within 1 month of treatment initia-
tion); gastrointestinal, hepatic, and pulmonary sTRAEs were
commonly observed within the first 3 months of treatment.
Endocrine and renal sTRAEs occurred later. It is important that
the management of any AE begins with ruling out other,
nondrug-related causes. However, signs and symptoms within
specific time periods could indicate a nivolumab-related event.
Of note, sTRAEs for all categories were observed past the
range of 4–12 weeks, emphasizing the need for continued vig-
ilance during treatment. Recently published evidence-based
guidelines for the management of immune-related AEs in
patients receiving immune checkpoint inhibitors emphasize
the importance of counseling patients to be aware of poten-
tial immune-related AEs and the importance of taking appro-
priate action [8].
For sTRAEs, skin events were the most common,
followed by gastrointestinal and hepatic events. Skin sTRAEs
are of special interest as skin AEs, particularly hand-foot
skin reaction (HFSR), are of clinical concern with the use of
sorafenib. Prior to the introduction of nivolumab, the oral
multikinase inhibitor sorafenib was the first evidence-based
treatment option approved for patients with advanced HCC
and is currently considered the standard of care [10, 11]. In
pivotal sorafenib trials, HFSR of any grade was reported in
21% and 45% of patients in predominantly Western and
Asian populations, respectively [12, 13]. HFSR usually pre-
sents with a range of symptoms from burning, tingling, and
skin erythema to pain, edema, and ulcerations in the
extremities; HFSR can interfere with simple daily activities,
such as walking or gripping objects [14, 15]. Based on cur-
rent study data, skin sTRAEs may be the first AEs that
patients experience following initiation of nivolumab treat-
ment, often developing within the first month. However, in
contrast to sorafenib, skin sTRAEs with nivolumab are com-
monly pruritus (21.4%) and rash (17.6%). Rash AEs were
mostly mild, with <1% frequency of grade 3/4 events. Skin
sTRAEs were manageable and resolved in 63.2% of patients
after treatment with topical corticosteroids.
Because patients with advanced HCC already have
hepatic morbidity, the incidence and severity of hepatic
sTRAEs with nivolumab treatment are important consider-
ations [16]. The low incidence of any-grade (14.1%) and
grade 3/4 (6.5%) hepatic sTRAEs in CheckMate 040 is there-
fore encouraging. Similarly, the incidence of gastrointestinal
sTRAEs was low (14.5%), with a low rate of grade 3/4
events (1.1%). Diarrhea accounted for 13.7% of gastrointes-
tinal sTRAEs, whereas colitis was uncommon (<1%).
Many patients (39.9%) who experienced sTRAEs were
treated with IMM, according to the relevant AE manage-
ment algorithm. Immune-related AEs potentially require
the use of IMM such as steroids. Clinicians should therefore
rule out other potential causes of the AE; for example,
treating diarrhea or pneumonitis from an infection with ste-
roids is unwarranted and risky [17]. A second important
aspect of clinical management is to taper steroids slowly
over at least a month. There is a risk of rebound if steroids
are tapered too quickly, and steroid withdrawal should be
gradual, according with standard medical practice [8].
Table 4. Summary of sTRAE reoccurence in patients who














Rechallenge occurred when the last nivolumab infusion was admin-
istered after the onset of an sTRAE. Includes events reported within
30 days after last dose of study therapy. Recurrent was defined as
an event that reoccurred on or after rechallenge.
Abbreviation: sTRAE, select treatment-related adverse event.
© 2020 The Authors.
The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Nivolumab Safety in Hepatocellular Carcinomae1538
The general approach for management of hepatic events
with nivolumab was based on cumulative data across tumor
types in patients with normal hepatic function. To account for
potential baseline liver dysfunction in patients with HCC, a
modified algorithm with adjusted upper limits for inclusion was
used in CheckMate 040 for the management of hepatic sTRAEs.
It is encouraging to note that only 7 of 37 patients with hepatic
sTRAEs required treatment with IMM (primarily steroids),
suggesting that nivolumab-related hepatic sTRAEs are manage-
able, even in patients with underlying liver dysfunction.
Reoccurrence of sTRAEs was uncommon. In patients
who were rechallenged with nivolumab, the initial sTRAE
only reoccurred in two patients, both of whom experienced
hepatic events. Most sTRAEs requiring treatment were
effectively managed by systemic corticosteroids.
Select TRAEs commonly resolved in 4–12 weeks following
dose delays or treatment with an IMM. Endocrine sTRAEs
may be resolved with low doses of systemic corticosteroids
[8], provided that patients are compliant with this therapy. In
such cases, regular monitoring of cortisol levels is useful.
Some endocrine sTRAEs, however, may not completely
resolve. For example, thyroid AEs such as hypothyroidism
could require lifetime hormone supplementation [17, 18].
The TTR of sTRAEs is variable, and the management of
each patient must be individualized. Nivolumab management
guides provide recommendations for monitoring and manag-
ing sTRAEs [19]. Many other practical recommendations and
guidelines are also available for health care professionals.
In CheckMate 040, nivolumab led to durable responses
and clinically meaningful survival and had a manageable
safety profile in an etiologically diverse population of
patients with advanced HCC [3]. Furthermore, the hepatic
sTRAEs often seen in patients with cirrhosis were readily
manageable. These efficacy and safety data suggest that
nivolumab has the potential to improve outcomes for
patients with advanced HCC.
Limitations of the current study include the non-
randomized design of the CheckMate 040 cohorts analyzed.
More information on the safety of nivolumab has been pro-
vided by the CheckMate 459 study, a randomized phase III trial
of nivolumab versus sorafenib as first-line treatment in
patients with advanced HCC (ClinicalTrials.gov: NCT02576509)
[20]. Although data are limited for patients with Child-Pugh
scores of 7 or higher (class B or C), the safety of nivolumab has
been evaluated in this population as part of the CheckMate
040 trial [21], and more data from this cohort are forthcoming.
CONCLUSION
In this safety analysis of sorafenib-naive or -experienced
patients with advanced HCC, nivolumab demonstrated a
manageable safety profile. Treatment with nivolumab was
generally well tolerated. TRAEs, other than endocrine
events, generally occurred early in treatment. A majority of
sTRAEs, including hepatic events, resolved with dose delays
and with the addition of IMM in a subset of patients.
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